Related Experiment Video

Updated: Jun 20, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

TrkB as a therapeutic target for ovarian cancer

Michelle K Y Siu1, Oscar G W Wong, Annie N Y Cheung

  • 1The University of Hong Kong, Queen Mary Hospital, Department of Pathology, Hong Kong, China.

Expert Opinion on Therapeutic Targets
|August 22, 2009
PubMed
Abstract

Insights

Tropomyosin-related kinase B (TrkB) is overexpressed in ovarian cancer, correlating with poor prognosis. Targeting TrkB and its ligand, brain-derived neurotrophic factor (BDNF), offers a promising therapeutic strategy for this lethal gynecological malignancy.

Area of Science:

  • Gynecologic Oncology
  • Molecular Oncology
  • Cancer Signaling

Background:

  • Ovarian cancer is a leading cause of cancer death globally, often presenting with metastasis and resistance to chemotherapy.
  • Poor prognosis in ovarian cancer is linked to late-stage diagnosis and treatment failure.
  • Overexpression of Tropomyosin-related kinase B (TrkB), a receptor tyrosine kinase, is observed in ovarian cancer and associated with adverse outcomes.

Purpose of the Study:

  • To review the functional roles of TrkB and its ligand, brain-derived neurotrophic factor (BDNF), in ovarian cancer.
  • To elucidate the downstream signaling pathways influenced by TrkB/BDNF in ovarian cancer.
  • To explore potential crosstalk between the TrkB/BDNF pathway and other molecular targets in ovarian cancer.

Main Methods:

  • Literature review of studies investigating TrkB and BDNF in ovarian cancer.
  • Analysis of signaling pathways downstream of TrkB activation.
  • Examination of potential therapeutic targeting strategies.

Main Results:

  • TrkB and BDNF play significant roles in ovarian cancer progression and survival.
  • Specific downstream signaling cascades activated by TrkB/BDNF contribute to tumorigenesis.
  • Interactions between TrkB/BDNF and other molecular pathways are implicated in ovarian cancer.

Conclusions:

  • The TrkB receptor and its ligand BDNF are critical players in ovarian cancer.
  • Targeting the TrkB/BDNF pathway presents a viable therapeutic avenue.
  • Further research into TrkB as a therapeutic target could improve patient survival in ovarian cancer.

More Related Videos

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...